Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2006

View Archived Issues

R&D highlights from the UBS Global Life Sciences Conference in New York: Abraxis BioScience

Snapshots of studies of the antibiotic efficacy of CS-023

FK-228 shows activity in ongoing metastatic hormone refractory prostate cancer trial

ZIO-101 demonstrates anticancer activity in patients with advanced disease

Promising activity seen with DJ-927 in advanced breast cancer

Biovitrum and Synphora sign agreement on JB-991 for psoriasis

Nautilus files IND for Belerofon

OPi and Vaccinex sign licensing agreement for anti-IL-6 antibody

Final efficacy results of GENASIS trial

MGA-031 awarded orphan drug status for recent-onset type 1 diabetes mellitus

Phase I study begins for next-generation anticoagulant M-118

Preparations for phase II study of NeuroVax in relapsing-remitting MS

DOV outlines new strategic direction

Phase I study evaluates CRS-100 in cancer patients with liver metastases

IMA-901 for renal cell cancer evokes immune responses in phase I study

European orphan drug status recommended for EndoTAG-1 in pancreatic cancer

In vivo efficacy of NXL-101 against multiresistant S. aureus

Ferrer present preclinical data on their candidate for dermal infections

Novel agents for pain, migraine, etc., imparted in recent patent literature

Novel wound-healing agents disclosed in recent Northwestern University patent

New compounds with potential in the treatment of neurological disorders reported

FDA requests additional phase III trial for Saforis

Avastin approved with chemotherapy for first-line treatment of NSCLC

Intercell begins regulatory process for Japanese encephalitis vaccine

R&D highlights from the UBS Global Life Sciences Conference in New York: Locus Pharmaceuticals

Orphan drug designation for 4975 in interdigital neuroma

Supplemental NDA filed for Advair Diskus in COPD

Riquent MAA to be withdrawn, with plans for resubmission

Researchers identify KALRN as novel CAD susceptibility gene

HLA-C identified as second susceptibility locus for multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.